NORD Refines Orphan Exclusivity Position
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.
More from Archive
More from Pink Sheet
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.